Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
This study is ongoing, but not recruiting participants.
First Received: September 30, 2002   Last Updated: July 10, 2009   History of Changes
Sponsor: Biogen Idec
Information provided by: Biogen Idec
ClinicalTrials.gov Identifier: NCT00046488
  Purpose

To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.


Condition Intervention Phase
Chronic Lymphocytic Leukemia
 Drug: IDEC-152
 Phase I

Study Type: Interventional
Study Design: Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Resource links provided by NLM:

MedlinePlus related topics: Leukemia, Adult Acute Leukemia, Adult Chronic
Drug Information available for: Lumiliximab
U.S. FDA Resources

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • Determine a recommended Phase II dose for the treatment of patients with relapsed or refractory CLL [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Characterize the safety profile of IDEC-152 [ Time Frame: 48 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluate the pharmacokinetics and pharmacodynamics of IDEC-152 in patients with relapsed or refractory CLL [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Evaluate the efficacy of IDEC-152 in patients with relapsed or refractory CLL [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: September 2002
Estimated Study Completion Date: December 2010
Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: IDEC-152
    6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed IRB-approved informed consent.
  • Greater than 18 years of age
  • Proof of CD23+ CLL or small lymphocytic lymphoma (SLL)
  • Progressive disease after at least 1 course of chemotherapy
  • Acceptable hematologic status, liver function, renal function, and pulmonary function
  • Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment

Exclusion Criteria:

  • Previous exposure to IDEC-152 or other anti-CD23 antibodies
  • Presence of HIV infection or AIDS
  • Serious nonmalignant disease
  • Active uncontrolled bacterial, viral or fungal infections.
  • Clinically active autoimmune disease
  • Pregnant or currently breast feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00046488

Locations
United States, California
Research Site
La Jolla, California, United States
Research Site
LaJolla, California, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, New York
Research Site
New York, New York, United States
Research Site
New Hyde Park, New York, United States
United States, Ohio
Research Site
Columbus, Ohio, United States
United States, Texas
Research Site
Houston, Texas, United States
Sponsors and Collaborators
Biogen Idec
  More Information

Publications:
Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55.
Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood. 2008 Feb 1;111(3):1594-602. Epub 2007 Nov 21.

Responsible Party: Biogen Idec ( Study MD )
Study ID Numbers: 152-20
Study First Received: September 30, 2002
Last Updated: July 10, 2009
ClinicalTrials.gov Identifier: NCT00046488     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Biogen Idec:
Chronic Lymphocytic Leukemia
Chronic Lymphoblastic Leukemia
Leukemia, Lymphoblastic, Chronic
CLL

Additional relevant MeSH terms:
Lymphatic Diseases
Leukemia
Neoplasms
Leukemia, Lymphoid
Immunoproliferative Disorders
 Neoplasms by Histologic Type
Immune System Diseases
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoproliferative Disorders
Leukemia, B-Cell

ClinicalTrials.gov processed this record on November 09, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services